Detalles de la búsqueda
1.
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.
Oncologist
; 27(6): e484-e493, 2022 06 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35429394
2.
Combi-TED: a new trial testing Tedopi® with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line.
Future Oncol
; 18(40): 4457-4464, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36946237
3.
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
Future Oncol
; 18(7): 771-779, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35068173
4.
The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma.
J Oncol Pharm Pract
; 28(2): 434-437, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34581219
5.
Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer.
J Oncol Pharm Pract
; 28(1): 199-202, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34581610
6.
Is lung ultrasound score a useful tool to monitoring and handling moderate and severe COVID-19 patients in the general ward? An observational pilot study.
J Clin Monit Comput
; 36(3): 785-793, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33948780
7.
The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level.
J Oncol Pharm Pract
; 27(5): 1245-1247, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34018861
8.
The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs.
J Oncol Pharm Pract
; 27(2): 445-447, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33356990
9.
Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness.
J Oncol Pharm Pract
; 27(4): 974-977, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33541208
10.
Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data.
Curr Opin Oncol
; 32(4): 269-273, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32541312
11.
The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer.
J Oncol Pharm Pract
; 26(6): 1486-1491, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32576084
12.
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study).
Oncologist
; 24(6): e318-e326, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30846513
13.
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
BMC Cancer
; 19(1): 283, 2019 Mar 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-30922323
14.
FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer.
Pancreatology
; 19(2): 325-330, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30704852
15.
First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugs.
Int J Colorectal Dis
; 33(11): 1505-1516, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30196427
16.
Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costs.
Int J Colorectal Dis
; 33(10): 1487-1491, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29804191
17.
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
Br J Cancer
; 116(3): 318-323, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28081548
18.
Tandem Tetrahydroisoquinoline-4-carboxylic Acid/ß-Alanine as a New Construct Able To Induce a Flexible Turn.
Chemistry
; 23(45): 10822-10831, 2017 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28467649
19.
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Int J Gynecol Cancer
; 27(9): 1872-1876, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28976446
20.
Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer.
J Oncol Pharm Pract
; 28(1): 194-198, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34558365